Back to HOME

Lipoprotein


DATA No : TLP4401 INFORMANT : Kazuo Kondo

NAME : apolipoprotein C-II

COMMON NAME:
SYMBOL: apo C-II
FORMULA: MOL.WT (average) :
BIOLOGICAL ACTIVITY
Function
Apo CII binds to lipoprotein lipase (LPL) and hydrolizes triglycerides.(Ref. 4403)
PHYSICAL AND CHEMICAL PROPERTIES
MELTING POINT:Molecular weight:8,837
Isoelectric point:4.9(Ref. 4401)

BOILING POINT:The number of amino acid residues :79

REFRACTIVE INDEX:Amino acid sequences:Further investigations are required.

OPTICAL ROTATION:Structure:The primary structure of apo C-II is comprised of single-stranded polypeptides. Amphiphilic helix structures are observed in segments 13-22, 28-38, and 43-51. Hydrophobic peptides in segments 66-78, 60-78, 55-78, and 50-78 do not bind to phospholipids, while the segment 43-49 is highly hydrophobic and has a helix structure, thus being involved in lipid binding.

DENSITY:Amino acid compositions (Ref. 4408)

SOLUBILITY:(Ref. 4402)
SPECTRAL DATA
UV SPECTRA:

IR SPECTRA:

NMR SPECTRA:

MASS SPECTRA:

OTHER SPECTRA:
CHROMATOGRAM DATA
Method of purification
After centrifugation, VLDL was separated from plasma by ultracentrifugation, which was defatted after dialysis.
SOURCE
Existing condition and distribution of lipoprotein
In blood, apo C-II binds to lipids, and is a structural element of VLDL and HDL
CHEMICAL SYNTHESIS
Sites of synthesis:The liver and the small intestine.
The rate of synthesis:1.6mg/kg/day
METABOLISM
Metabolism
Apo C-II is synthesized in the liver and small intestine, and present in VLDL. After activating LPL, apo C-II is transferred from VLDL to HDL.
Half life:1.0 days(Ref. 4404/4405)
GENETIC INFORMATION
Genetic information
Gene locus:19;pter-q13
Genearrangement(DNA)(Ref. 4115)
Information of genetic diseases:Information on genetic diseases (Apo C-II deficiency).
Phenotypes:Further investigations are required.(Ref. 4406)
NOTE
Standard range:1.6- 4.2mg/dl (in human sera)
Diseases and drugs that induce abnormal levels of apo C-II.:Apo C-II deficiency
Analytical methods:TIA,ELISA,Nephelometry ,SRIDetc.
REFERENCES
[4115]
AUTHOR:Sharpe, C. R., Sidoli, A., Shelley, C. S., Lucero, M. A., Shoulders, C. C., and Baralle, F. E.
TITLE:Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance PubMed ID:6328445
JOURNAL:Nucleic Acids Res.
VOL:12 PAGE : 3917-3932 (1984)
[TOP]

[4401]
AUTHOR:Sparrow, J. T., and Gotto, A. M., Jr.
TITLE:Phospholipid binding studies with synthetic apolipoprotein fragments PubMed ID:6772077
JOURNAL:Ann N Y Acad Sci.
VOL:348 PAGE : 187-211 (1980)
[TOP]

[4402]
AUTHOR:Brown, W. V., Levy, R. I., and Fredrickson, D. S.
TITLE:Studies of the proteins in human plasma very low density lipoproteins PubMed ID:4981584
JOURNAL:J Biol Chem.
VOL:244 PAGE : 5687-5694 (1969)
[TOP]

[4403]
AUTHOR:LaRosa, J. C., Levy, R. I., Herbert, P., Lux, S. E., and Fredrickson, D. S.
TITLE:A specific apoprotein activator for lipoprotein lipase PubMed ID:5459123
JOURNAL:Biochem Biophys Res Commun.
VOL:41 PAGE : 57-62 (1970)
[TOP]

[4404]
AUTHOR:Eisenberg, S., and Rachmilewitz, D.
TITLE:Interaction of rat plasma very low density lipoprotein with lipoprotein lipase-rich (postheparin) plasma PubMed ID:170350
JOURNAL:J Lipid Res.
VOL:16 PAGE : 341-351 (1975)
[TOP]

[4405]
AUTHOR:Wu, A. L., and Windmueller, H. G.
TITLE:Identification of circulating apolipoproteins synthesized by rat small intestine in vivo PubMed ID:632283
JOURNAL:J Biol Chem.
VOL:253 PAGE : 2525-2528 (1978)
[TOP]

[4406]
AUTHOR:Yamamura, T., Sudo, H., Ishikawa, K., and Yamamoto, A.
TITLE:Familial type I hyperlipoproteinemia caused by apolipoprotein C-II deficiency PubMed ID:227429
JOURNAL:Atherosclerosis.
VOL:34 PAGE : 53-65 (1979)
[TOP]

[4408]
AUTHOR:Jackson,R.L., and Holdsworth,G.(1986) Isolation and Characterization of Apolipoproteins C-I, C-II, C-III, in Methods in ENZYMOLOGY Vol.128 (Segrest J.P., and Albers J.J., eds), pp223-246, Academic Press, Inc.
TITLE:
JOURNAL:
VOL: PAGE : - ()
[TOP]

Last updated June 19, 2007. Copyright © 1989-2007 Japanese Conference on the Biochemistry of Lipids (JCBL). All rights reserved.